Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccinati...
Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan
About this item
Full title
Author / Creator
Matsuura, Tomoka , Fukushima, Wakaba , Nakagama, Yu , Kido, Yasutoshi , Kase, Tetsuo , Kondo, Kyoko , Kaku, Natsuko , Matsumoto, Kazuhiro , Suita, Asae , Komiya, Eriko , Mukai, Emiko , Nitahara, Yuko , Konishi, Ayako , Kasamatsu, Ayane , Nakagami-Yamaguchi, Etsuko , Ohfuji, Satoko , Kaneko, Yukihiro , Kaneko, Akira , Kakeya, Hiroshi and Hirota, Yoshio
Publisher
Netherlands: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Highlights•Two BNT162b2 doses resulted in adequate anti-receptor-binding domain (RBD) antibody response. •Anti- receptor-binding domain (RBD) titers varied by age but not sex and BMI. •Anti-RBD titers by two assays 6 months after vaccination showed different kinetics. •The results of single immunoassays should be interpreted with caution.
Alternative Titles
Full title
Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan
Authors, Artists and Contributors
Author / Creator
Fukushima, Wakaba
Nakagama, Yu
Kido, Yasutoshi
Kase, Tetsuo
Kondo, Kyoko
Kaku, Natsuko
Matsumoto, Kazuhiro
Suita, Asae
Komiya, Eriko
Mukai, Emiko
Nitahara, Yuko
Konishi, Ayako
Kasamatsu, Ayane
Nakagami-Yamaguchi, Etsuko
Ohfuji, Satoko
Kaneko, Yukihiro
Kaneko, Akira
Kakeya, Hiroshi
Hirota, Yoshio
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9376311
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9376311
Other Identifiers
ISSN
0264-410X
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2022.08.018
